Repligen EPS - Earnings per Share 2010-2024 | RGEN

Repligen earnings per share (EPS) for the twelve months ending June 30, 2024 was $-0.02, a 100.83% decline year-over-year.

  • Repligen EPS for the quarter ending June 30, 2024 was $0.06, a 82.86% decline year-over-year.
  • Repligen 2023 annual EPS was $0.74, a 77.16% decline from 2022.
  • Repligen 2022 annual EPS was $3.24, a 44.64% increase from 2021.
  • Repligen 2021 annual EPS was $2.24, a 101.8% increase from 2020.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.

Repligen EPS - Earnings per Share 2010-2024 | RGEN

  • Repligen EPS for the quarter ending June 30, 2024 was $0.06, a 82.86% decline year-over-year.
  • Repligen 2023 annual EPS was $0.74, a 77.16% decline from 2022.
  • Repligen 2022 annual EPS was $3.24, a 44.64% increase from 2021.
  • Repligen 2021 annual EPS was $2.24, a 101.8% increase from 2020.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$173B
Vertex Pharmaceuticals (VRTX)$127.1B
Gilead Sciences (GILD)$114.2B
Bristol Myers Squibb (BMY)$112.1B
CSL (CSLLY)$91B
Regeneron Pharmaceuticals (REGN)$89.7B
GSK (GSK)$74.4B
Argenex SE (ARGX)$35.2B
Alnylam Pharmaceuticals (ALNY)$35.2B
Biogen (BIIB)$25.4B
BioNTech SE (BNTX)$25.4B
Illumina (ILMN)$24.2B
Moderna (MRNA)$19.9B
BeiGene (BGNE)$19.7B
Incyte (INCY)$15.6B
Genmab (GMAB)$14.8B
Insmed (INSM)$13B
Vaxcyte (PCVX)$13B
BioMarin Pharmaceutical (BMRN)$12.6B
Sarepta Therapeutics (SRPT)$12.2B
Bio-Techne Corp (TECH)$12B
Exelixis (EXEL)$10.1B
Exact Sciences (EXAS)$10.1B
QIAGEN (QGEN)$10B
Revolution Medicines (RVMD)$9.9B
Intra-Cellular Therapies (ITCI)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$8.7B
Ascendis Pharma (ASND)$7.8B
Halozyme Therapeutics (HALO)$7.7B